These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 16512831

  • 1. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
    Wåhlander K, Eriksson H, Lundström T, Billing Clason S, Wall U, Nyström P, Wessman P, Schulman S, THRIVE III Investigators.
    Br J Haematol; 2006 Apr; 133(1):68-77. PubMed ID: 16512831
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
    Schulman S, Lundström T, Wålander K, Billing Clason S, Eriksson H.
    Thromb Haemost; 2005 Oct; 94(4):820-4. PubMed ID: 16270637
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B, Palareti G.
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The role of ximelagatran in the treatment of venous thromboembolism.
    Schulman S.
    Pathophysiol Haemost Thromb; 2005 Aug; 34 Suppl 1():18-24. PubMed ID: 15812200
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
    Harenberg J, Jörg I, Weiss C.
    Int J Toxicol; 2006 Aug; 25(3):165-9. PubMed ID: 16717032
    [Abstract] [Full Text] [Related]

  • 11. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin.
    Brouwer JL, Lijfering WM, Ten Kate MK, Kluin-Nelemans HC, Veeger NJ, van der Meer J.
    Thromb Haemost; 2009 Jan; 101(1):93-9. PubMed ID: 19132194
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
    Koscielny J, Kiesewetter H, Jörg I, Harenberg J.
    Clin Appl Thromb Hemost; 2007 Jul 24; 13(3):299-307. PubMed ID: 17636192
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
    Strandberg K, Svensson PJ, Ohlin AK.
    Thromb Res; 2007 Jul 24; 121(2):145-51. PubMed ID: 17499343
    [Abstract] [Full Text] [Related]

  • 20. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
    Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY, Estrogen and Thromboembolism Risk (ESTHER) Study Group.
    Circulation; 2005 Nov 29; 112(22):3495-500. PubMed ID: 16301339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.